The BEACON Study (Breast Cancer Outcomes With NKTR-102)

NCT01492101 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

852

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Recurrent Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: NKTR-102
DRUG: Treatment of Physician's Choice (TPC)

Sponsor

Nektar Therapeutics